经咽鼓管鼓室途径注射地塞米松治疗突发性聋

Pharyngotympanic tube intratympanic dexamethasone injections for sudden sensorineural hearing loss

目的观察经咽鼓管鼓室注入地塞米松(简称PTIDI)治疗突发性聋(突聋)的疗效。方法对18例常规方法治疗无效的突聋患者采用经咽鼓管鼓室径路注入地塞米松,首次剂量为5mg,此后,每天重复注药1次,每次5mg,共7次,总剂量35mg,用药期间密切观察记录听力改变,耳鸣和眩晕等情况。结果18例患者于治疗完成后两周复查纯音测听。痊愈1例;显效5例,0.25～4kHz听阈平均提高50.2dB;有效1例,平均提高19dB;无效11例;有效率为38.9%(7/18)。结论PTIDI治疗突聋疗效好,操作方便,避免全身用药可能产生的不良反应,为常规方法治疗无效的突聋患者提供了再次治疗的机会。

Objective To investigate the efficacy of pharyngotympanic tube intratympanic dexamethasone injection （PTIDI） for patients with sudden sensorineural hearing loss （SSNHL）. Methods Dexamethasone （5mg） was injected into the middle ear of 18 patients with SSNHL via the pharyngotympanic tube. The injection was repeated every day for a total of 7 doses （35 mg）. Results After two-week follow-up one patient （5.6%） completely recovered. Seven of the 18 patients （38.9%） demonstrated a 19-65 dB improvement in PTA and the remaining 11 （61.1%） had no response. Conclusion PTIDI is a simple and effective treatment for SSNHL. It provides an opportunity to cure refractory SSNHL.